Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94388ArticlesСтатьиResearch ArticleKey features of candesartan application in clinical practiceОсобенности применения кандесартана в клинической практике‌‌‌‌EvdokimovaA. GЕвдокимоваАнна Григорьевна

д-р мед. наук, проф. каф. госпитальной терапии №2 ГБОУ ВПО МГМСУ им А.И.Евдокимова

Aevdokimova@rambler.ruLozhkinaM. VЛожкинаМарина Витальевна

канд. мед. наук, доц. каф. госпитальной терапии №2 ГБОУ ВПО МГМСУ им А.И.Евдокимова

KovalenkoE. VКоваленкоЕлена Викторовна

канд. мед. наук, доц. каф. госпитальной терапии №2 ГБОУ ВПО МГМСУ им А.И.Евдокимова

A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian FederationГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России15012016181VOL 18, NO1 (2016)ТОМ 18, №1 (2016)545928122021Copyright ©; 2016, Consilium MedicumCopyright ©; 2016, ООО "Консилиум Медикум"2016Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94388

The article deals with the literature review concerning the candesartan cilexetil application in patients with arterial hypertension, chronic heart failure, chronic kidney disease, diabetes mellitus and other conditions. Particular attention is paid to the special aspects of the pharmacokinetics and pharmacodynamics of the drug, organoprotective properties, metabolic neutrality and safety application.

В статье представлен литературный обзор по применению кандесартана цилексетила у пациентов с артериальной гипертензией, хронической сердечной недостаточностью, хронической болезнью почек, сахарным диабетом и другими состояниями. Особое внимание уделено особенностям фармакокинетики и фармакодинамики препарата, органопротективным свойствам, его метаболической нейтральности и безопасности применения.

arterial hypertensionchronic heart failurechronic kidney diseasediabetes mellituscandesartanартериальная гипертензияхроническая сердечная недостаточностьхроническая болезнь почексахарный диабеткандесартанАндрущишина Т.Б., Морозова Т.Е. Антагонисты рецепторов ангиотензина II при лечении кардиоваскулярных заболеваний // Consilium Medicum. 2009; 11 (5): 96-101.Jonston C.I. Renin - angiotensin system: a dual tissue and hormonal system for cardiovascular control. Am J Hypertens 1992; 10: S13-S26.Гиляревский С.Р. Современные возможности блокады ренин - ангиотензиновой системы: остаются ли ингибиторы ангиотензинпревращающего фермента препаратами первого ряда? // Consilium Medicum. 2010; 12 (5): 18-23.Остроумова О.Д., Хорьков С.А., Копченов И.И. Возможности антагонистов рецепторов к ангиотензину II в органопротекции у больных с артериальной гипертонией: значение для клинической практики // Consilium Medicum. 2009; 11 (5): 29-37.Евдокимова А.Г., Ложкина М.В., Коваленко Е.В., Евдокимов В.В. Клиническая эффективность ирбесартана у пациентов с сердечно - сосудистыми заболеваниями. Сердце. 2012; 11 (6): 364-8.Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. Доказательная история кандесартана: прошлое, будущее и настоящее. Сердечная недостаточность. 2015; 16 (5): 303-10.Сиренко Ю.Н., Донченко Н.В. Место кандесартана в современной терапии сердечно - сосудистых заболеваний: обзор доказательств. Артериальная гипертензия. 2011; 4 (18): 114-26.Hubner R, Hogemann A.M, Sunzel M, Riddell J.C. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11 (Suppl. 2): S19-S25.Trenkwalder P, Lehlovirta M, Dahl K. Long - term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type 2 diabetes. J Hum Hypertens 1999; 13 (Suppl. 1): S81-S83.Inada Y, Ojima M, Kanagawa R et al. Pharmacologic properties of candesartan cilexetil - possible mechanisms of long - term antihypertensive action. J Hum Hypertens 1999; 13 (Suppl. 1): S75-S80.Mc Clellan K.J, Goa K.L. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998; 56: 847-69.Abrahamsson Т, Karp L, Brabdl-Eliasson I.I el al. Candesartan causes long - last antagonism of angiotensin II receptor - mediated contractile effects in isolated vascular preparations: a comparison with irbesartan, losartan and its active metabolite (EXP- 3174). Blood Pressure 2000; 9 (Abstr. Suppl.): 1-52.Linger T. Differences among angiotensin II type 1 receptor blockers: characterization of candesartan cilexetil. Blood Pressure 2000; 9 (Suppl. 1): 14-8.Vanderheyden P.M.L, Fierens F.L.P, De Backer J.P, Vauquelin G. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type I receptors. Biochem Pharmacol 2000; 59: 927-35.Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302: 237-43.Easthope S.E, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62: 1253-87.Cuspidi C, Muiesan M.L, Valagussa L еt al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-300.Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; p. 1195-201.Escobar C, Barrios V, Calderon A et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker - based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) 2008; 10: 208-14.Penicka M, Gregor P, Kerekes R et al. Candesartan use in Hypertrophic And Non - obstructive Cardiomyopathy Estate (CHANCE) Study. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn 2009; 11: 35-41.Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double - blind intervention trial. J Hypertens 2003; 21: 875-86.Kasanuki H, Hagiwara N, Hosoda S et al. HIJ-CREATE Investigators. Angiotensin II receptor blockerbased vs. nonangiotensin II receptor blockerbased therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203-12.De Rosa M.J. Angiotensin II receptor blockers and cardioprotection. Vasc Health Risk Manag 2010; 6: 1047-63.Burgess E, Muirhead N, Rene de Cotret P et al. SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20: 893-900.Mogensen C.E, Neldam S, Tikkanen I et al. For the CALM study group. Randomised controlled trial of dual blockade of renin - angiotensin system in patients with hypertension, microalbuminuria, and non - insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-4.Norris S, Weinstein J, Peterson K, Thakurta S. Drug Class Review. Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers. Drug Effectiveness Review Project. Oregon Health & Science University 2009.Pfeffer M.A, Swedberg K, Granger C.B et al. For the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.Mc Murray J.J.V, Ostergren J, Swedberg K et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.Granger C.B, Mc Murray J.J.V, Yusuf S et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6.Yusuf S, Pfeffer M.A, Swedberg K et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-81.Ducharme A, Swedberg K, Pfeffer M.A et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86-92.Grassi G, Seravalle G, Dell’Oro R еt al. For CROSS Study. Comparative effects of candesartan and hydrochlortiazide on blood pressure, insulin sensitivity and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761-9.Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; 6 (9): 1195-201.Kasanuki H, Hagiwara N, Hosoda S et al. Angiotensin II receptor blocker - based vs. non - angiotensin II receptor blocker - based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREA- TE). Eur Heart J 2009; 30 (10): 1203-12.Sjolie A.K, Porta M, Parving H.H et al. The Diabetic REtinopathy Candersantan Trials (DIRECT) Programme: baseline characteristics. JRAAS 2005; 6 (1): 25-32.Suzuki T, Nozawa T, Fujii N et al. Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease. Coron Artery Dis 2011; 22: 352-35.Schrader J, Lüders S, Kulschewski A et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699-703.Эффективность приема блокатора рецепторов ангиотензина II кандесартана в острой фазе инсульта: результаты рандомизированного исследования SCAST (Scandinavian Candesartan Acute Stroke Trial). Доказательная кардиология. 2011; 2: 17-25.